Ariana® expands operations to USA, appoints James M. Shanahan VP business development of subsidiary “Ariana Data Intelligence, Inc.”
Ariana Pharma, a provider of “non-statistical” clinical data analysis technology to the pharmaceutical industry including the FDA, announces today that it has expanded its global operations by establishing a permanent US office in Cambridge, MA to service growing demand for its unique and powerful data analytics technology KEM®.
In conjunction with the opening, Ariana has appointed James M. Shanahan as VP of Business Development. James was previously a co-founder and is current board member of SynDevRx, Inc., an oncology-focused biotech company and was a cofounder and VP Corporate Development of JAM Technologies, Inc. James brings 15 years business development and marketing experience to Ariana.
“The US pharma and biotech markets tend to be early technology adopters, and are searching for better data analytics tools to advance Personalized Medicine using all the new biomarker, genomic, proteomic and metabolomic data now being generated,” said Dr. Mohammad Afshar, President and CEO of Ariana Pharma. “Our KEM technology is the only proven approach that can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials.”
James Shanahan believes Ariana offers something special and desperately needed by the pharmaceutical industry. “Companies spend tens of millions of dollars generating data. Now, it’s all about making sense of that data, and KEM is a real game-changer for the pharma and biotech industries. It identifies useful, complex biological relationships that statistics routinely misses.”
KEM – or Knowledge Extraction and Management – is an association rules-based (non-statistical) analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect. KEM optimizes clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints and saving sponsors both time and cash.